02:16 PM EDT, 06/12/2024 (MT Newswires) -- Palatin Technologies ( PTN ) said Wednesday it has started a phase 2 clinical trial to assess the safety and efficacy of bremelanotide, a melanocortin 4 receptor agonist, administered alongside tirzepatide, for treating obesity.

Topline data from the study, which will involve up to 60 patients who are actively on tirzepatide across five sites in the US, is anticipated by the end of the year, the company said.

The company's shares were up nearly 4% in recent trading.

Price: 1.92, Change: +0.07, Percent Change: +3.78